

ORIGINAL RESEARCH

Age-Specific Risk Factors for Advanced Stage Colorectal Cancer, 1981–2013

Kevin J. Moore, MD, MPH¹; Daniel A. Sussman, MD, MSPH^{2,3}; Tulay Koru-Sengul, PhD, MHS^{1,3}

Accessible Version: www.cdc.gov/pcd/issues/2018/17_0274.htm

Suggested citation for this article: Moore KJ, Sussman DA, Koru-Sengul T. Age-Specific Risk Factors for Advanced Stage Colorectal Cancer, 1981–2013. *Prev Chronic Dis* 2018;15:170274. DOI: <https://doi.org/10.5888/pcd15.170274>.

PEER REVIEWED

Abstract

Introduction

Epidemiologic studies have identified an increase in colorectal cancer (CRC) among younger adults. By using a statewide population-based cancer registry, this study examines sociodemographic and clinical disparities in CRC and characterizes advanced stage CRC risk factors with specific attention to age-specific risk factors.

Methods

Data from the Florida Cancer Data System from 1981 through 2013 were analyzed for adult CRC patients. Patients were divided into 2 age groups: younger than 50 years and 50 years or older. Stage of presentation was categorized as early (localized) or advanced (regional or distant). Multivariable logistic regression models adjusted for sociodemographic and clinical characteristics were fitted to identify risk factors for advanced stage CRC presentation. Adjusted odds ratios were calculated with 95% confidence intervals.

Results

From 1981 through 2013, there were 182,095 Florida adults diagnosed with CRC. Those aged younger than 50 years were significantly more likely to have advanced stage CRC compared with those aged 50 or older. Among those younger than 50 years, current and former tobacco smokers and those of black or other race were significantly more likely to have advanced stage CRC.

Among those aged 50 or older, Hispanics had significantly higher risk of advanced stage presentation compared with non-Hispanics, although this association was not significant in those younger than 50 years.

Conclusion

We identified significant age-specific risk factors for advanced stage CRC presentation. With CRC incidence on the rise among younger adults, it is important to identify and to target screening and interventions for groups at high risk for advanced stage CRC presentation.

Introduction

Despite a decrease in colorectal cancer (CRC) among all adults, recent epidemiologic studies have identified an increase in incidence among adults younger than 50 years of age (1). CRC is among the most common cancers diagnosed in the United States for adults younger than 50 years of age (2). Among all US adults, CRC is the third most commonly diagnosed cancer in both men and women (3). In 2017 in the United States, an estimated 135,430 people were predicted to be diagnosed with CRC and about 50,260 people were predicted to die from the disease (4). In Florida, the 2014 age-adjusted incidence and mortality rates were 35.4 (95% confidence interval [CI], 34.6–36.1) and 13.0 (95% CI, 12.6–13.5), respectively (5). Florida includes specific counties with some of the highest CRC mortality rates nationally (6).

Advanced stage presentation and diagnosis of CRC portends significantly worse survival outcomes for both younger and older adults (7). By using a statewide population-based cancer registry, this study examines sociodemographic and clinical disparities in CRC cases among adults and characterizes advanced stage CRC diagnosis risk factors with specific attention to age-specific risk factors.



The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

Methods

Data from the Florida Cancer Data System (FCDS) with the linkage to the 2000 US census were analyzed for patients with primary CRC who were aged 18 years or older for 1981 through 2013. Patients who had missing values for age, race, ethnicity, neighborhood socioeconomic status (SES), and Surveillance, Epidemiology, and End Results (SEER) Program tumor stage at presentation were excluded from the analysis.

Sex (female, male), race (white, black, others), ethnicity (Hispanic, non-Hispanic), and smoking status (never, current, former, unknown) were self-reported. The FCDS registry does not contain information regarding patient SES at the time of cancer diagnosis. To be able to incorporate SES into the statistical analysis, we used data from the 2000 US Census to provide a proxy for individual SES. Patients' US census tract at the time of cancer diagnosis is used for the linkage. Patients' SES at the time of diagnosis were approximated by neighborhood level SES, which is determined by the patient's US census tract as the percentage of people living below poverty level as low (20% to 100%), middle-low (10% to <20%), middle-high (5% to <10%), and highest (0% to <5%). Age at diagnosis was divided into younger than 50 years or 50 years or older to align with the starting age for CRC screening recommended by the US Preventive Services Task Force (8). Anatomic sites were colon (ascending, transverse, descending, sigmoid), flexure (hepatic, splenic), rectosigmoid junction, and rectum. Individuals who did not have a specified primary anatomic site in the colon or rectum (ie, colon, not otherwise specified) were also excluded from the analysis. The primary clinical outcome, SEER tumor stage at diagnosis, was categorized as early (localized) or advanced (regional or distant) as a dichotomous variable.

Multivariable logistic regression models for all patients and by age group were fitted to identify risk factors for advanced stage CRC presentation. Adjusted odds ratios (AORs) and 95% CIs were calculated and adjusted for sociodemographic and clinical characteristics for the whole sample as well as by age group. All statistical analyses were completed by using SAS v.9.4 (SAS Institute, Inc). The study was approved by the Florida Department of Health (DOH) and University of Miami institutional review boards.

Results

In total, 277,562 adults were diagnosed with primary CRC during 1981 through 2013. There were 182,095 adults who satisfied the inclusion and exclusion criteria. Most were aged 50 years or older (93.0%) (Table 1). Approximately 60% of all cases were diagnosed at advanced stage (42.7% regional, 18.9% distant), and among those younger than 50 years, 69.6% were diagnosed at the

advanced stage (44.7% regional, 25.4% distant). In patients younger than 50 years with advanced stage presentation, most were men (52.6%), white (78.9%), and non-Hispanic (84.6%). Among patients younger than 50 years, the mean age of diagnosis was 42.5 years (95% CI, 42.4–42.6), while the mean age of diagnosis for those 50 or older was 71.7 (95% CI, 71.7–71.8). Patients younger than 50 years had a greater proportion of current smokers compared with those 50 or older. The most common anatomic site for advanced stage presentation was sigmoid colon for both the younger (27.8%) and older (27.2%) age groups.

Patients younger than 50 years were significantly more likely to present with advanced stage CRC compared with those aged 50 or older (AOR, 1.53; 95% CI, 1.47–1.60) (Table 2). Among patients younger than 50 years, black (AOR, 1.15; 95% CI, 1.03–1.29) and other race (AOR, 1.43; 95% CI, 1.10–1.84) had significantly higher odds of advanced stage CRC presentation compared with whites. Compared with the rectum, all anatomic sites showed significantly higher odds of advanced stage presentation in both age groups. For patients 50 years or older, Hispanics had significantly higher odds of advanced stage presentation compared non-Hispanics, although this association was not significant in those aged less than 50 years.

Discussion

Although patients aged less than 50 years are less likely to have CRC, our results demonstrate that these patients are significantly more likely to present with advanced stage CRC. Advanced stage CRC diagnosis is linked to significantly worse survival for all age groups (7). These results support past studies showing higher rates of advanced stage CRC presentation among those aged less than 50 years (2). Advanced stage CRC diagnosis may be attributable to misdiagnosis, genetic predisposition, or lack of knowledge regarding CRC symptoms (9). Consequently, recognizing and acknowledging risk factors for advanced stage CRC are necessary for earlier detection.

One of the most significant risk factors for advanced stage presentation among patients younger than 50 years was being black or other race. Higher rates of advanced stage presentation among blacks may be attributable to decreased awareness or patient attitudes toward CRC screening (10). These barriers prevent timely screening even in the presence of CRC symptoms. In addition, epidemiological studies have shown blacks develop CRC earlier than whites do (11). In terms of sex, women were significantly less likely to present with late-stage CRC in those younger

than 50 years; however, there was no significant difference between men and women among those aged 50 or older. Low awareness and limited screening coupled with a predisposition for earlier CRC development warrant targeted public health efforts to raise awareness for CRC signs and symptoms as well as screening.

Being a patient younger than 50 years or being a former or current smoker was a significant predictor of having advanced CRC presentation. Although there is some debate regarding the role of tobacco smoking on CRC development, our results show that current and former smokers have significantly increased risk of advanced stage CRC presentation (12,13). Future studies are necessary to further discern the role of tobacco smoking in CRC development and progression.

In total, Hispanics had fewer cases of CRC compared with non-Hispanics. Studies have shown that Hispanics have both lower rates of CRC incidence and mortality (14). Our results show that Hispanics have significantly higher risk for advanced presentation of CRC among patients aged 50 or older, whereas the risk was not significantly increased among those aged less than 50 years. Pollack et al reported that Hispanics have lower rates of CRC screening, which may account for the increased rates of advanced CRC presentation in our results (15). The lower rates of screening among Hispanics may be attributable to limited health insurance. In addition, barriers to CRC screening in the Hispanic population include limited education, lower socioeconomic status, and cultural barriers (16,17). In terms of CRC screening among the Florida population, Hispanics report lower rates of fecal occult blood test (FOBT) testing and sigmoidoscopy or colonoscopy (18). Culturally appropriate public health interventions are necessary to increase CRC awareness and screening among the Hispanic population.

In terms of anatomic site, we found that there was a significantly lower risk of advanced stage CRC of the rectum across all ages, yet the rectum was the second most common site for tumor after behind the sigmoid colon. Siegel et al noted that rectal cancer incidence was increasing at a greater rate than colon cancer among patients aged less than 50 years (1). In our study, patients aged less than 50 years had significantly increased risk for advanced presentation for tumors arising outside of the rectum. This finding was also true for patients aged 50 or older, but the risks were higher in those younger than 50 years compared with those 50 or older across all locations. CRC presents differently depending on tumor location, and screening and awareness efforts should emphasize the different CRC presentations. Although data suggest that ana-

tomic site does not significantly influence CRC presentation, anatomic location of CRC presentation may affect screening modality choice. Immunochemical testing such as FOBT has better sensitivity for detecting left-sided lesions compared with right-sided lesions (19).

This study is not without limitations. The FCDS database does not contain lifestyle habits such as dietary intake, which is significantly linked to CRC development (20). In addition, this cancer registry lacks genetic information and family history; both play a role in earlier CRC development. FCDS also does not include information about patients' comorbidities such as diabetes and obesity, which could affect the risk and the stage of cancer.

Routine screening for individuals aged less than 50 years is not recommended unless the individuals are considered at high risk. However, multiple noninvasive CRC screening modalities such as FOBT have potential for noninvasive screening in high-risk populations (21). These noninvasive CRC screening modalities may offer an opportunity to increase CRC screening in groups with elevated risk factors for advanced stage presentation.

Our study highlights the increased risk for advanced stage CRC presentation in patients younger than 50 years compared with those aged 50 or older. With CRC incidence on the rise in younger US adults, raising awareness for CRC screening in high-risk groups is imperative to improve earlier detection. Increased awareness among health professionals is also necessary to address and to investigate potential signs of CRC in high-risk populations. Our results show that there are clear sociodemographic disparities in advanced stage CRC presentation. The increased risk for advanced stage CRC among patients younger than 50 years and select sociodemographic groups merits further investigation. Future efforts are warranted to further improve CRC screening and awareness among younger adults.

Acknowledgments

We have no conflicts of interest to report. There was no funder or sponsor role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This study was approved by institutional review boards from the University of Miami and the Florida DOH. The Florida cancer incidence data used in this report were collected by the FCDS, the statewide cancer registry funded by the Florida DOH and the Centers for Disease Control and Prevention's National Program of Cancer Registries. The views expressed herein are solely those of the authors and do not necessarily reflect those of the DOH or the FCDS.

Author Information

Corresponding Author: Tulay Koru-Sengul, PhD, MHS, Associate Professor, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14 St, Locator code R669, Miami, FL 33136. Telephone: 305-243-2618. Email: tsengul@med.miami.edu.

Author Affiliations: ¹Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida. ²Department of Medicine, University of Miami School of Medicine, Miami, Florida. ³Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida.

References

1. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. *J Natl Cancer Inst* 2017; 109(8):djjw322.
2. Fairley TL, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998–2001. *Cancer* 2006; 107(5,Suppl):1153–61.
3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017;67(3):177–93.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66(1):7–30.
5. United States Cancer Statistics. 1999–2014 Incidence and Mortality Web-based Report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2017. <https://nccd.cdc.gov/USCS/statevsnational.aspx?Year=2014&Variable1=Florida>. Accessed May 17, 2017.
6. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C, Stubbs RW, Bertozzi-Villa A, Morozoff C, et al. Trends and patterns of disparities in cancer mortality among US counties, 1980–2014. *JAMA* 2017;317(4):388–406.
7. Tannenbaum SL, Hernandez M, Zheng DD, Sussman DA, Lee DJ. Individual- and neighborhood-level predictors of mortality in Florida colorectal cancer patients. *PLoS One* 2014; 9(8):e106322.
8. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. *JAMA* 2016; 315(23):2564–75. Errata in *JAMA* 2016;316(5):545 and *JAMA* 2017;317(21):2239.
9. O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? *World J Surg* 2004;28(6):558–62.
10. Greiner KA, Born W, Nollen N, Ahluwalia JS. Knowledge and perceptions of colorectal cancer screening among urban African Americans. *J Gen Intern Med* 2005;20(11):977–83.
11. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, Romero Y, et al. Colorectal cancer in African Americans. *Am J Gastroenterol* 2005;100(3):515–23, discussion 514. Erratum in *Am J Gastroenterol* 2005;100(6):1432.
12. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2001; 10(7):725–31.
13. Parajuli R, Bjerkaas E, Tverdal A, Selmer R, Le Marchand L, Weiderpass E, et al. The increased risk of colon cancer due to cigarette smoking may be greater in women than men. *Cancer Epidemiol Biomarkers Prev* 2013;22(5):862–71.
14. O’Brien K, Cokkinides V, Jemal A, Cardinez CJ, Murray T, Samuels A, et al. Cancer statistics for Hispanics, 2003. *CA Cancer J Clin* 2003;53(4):208–26. Erratum in *CA Cancer J Clin* 2003;53(5):314.
15. Pollack LA, Blackman DK, Wilson KM, Seeff LC, Nadel MR. Colorectal cancer test use among Hispanic and non-Hispanic U.S. populations. *Prev Chronic Dis* 2006;3(2):A50.
16. Vidal L, LeBlanc WG, McCollister KE, Arheart KL, Chung-Bridges K, Christ S, et al. Cancer screening in US workers. *Am J Public Health* 2009;99(1):59–65.
17. Stefanidis D, Pollock BH, Miranda J, Wong A, Sharkey FE, Rousseau DL, et al. Colorectal cancer in Hispanics: a population at risk for earlier onset, advanced disease, and decreased survival. *Am J Clin Oncol* 2006;29(2):123–6.
18. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. BRFSS prevalence and trends data. 2015. <https://www.cdc.gov/brfss/brfssprevalence/>. Accessed May 17, 2017.
19. Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. *Br J Cancer* 2011;104(11):1779–85.
20. Baena R, Salinas P. Diet and colorectal cancer. *Maturitas* 2015;80(3):258–64.
21. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. *CA Cancer J Clin* 2008;58(3):161–79.

Tables

Table 1. Sociodemographic Characteristics of Colon Cancer Patients, by Age Group, Florida Cancer Data System, 1981–2013

Characteristic	All, n (%) ^b	Age Group and Stage Presentation ^a			
		<50 years		≥ 50 years	
		Early, n (%) ^b	Advanced, n (%) ^b	Early, n (%) ^b	Advanced, n (%) ^b
Total	182,095 (100.0)	3,861 (2.1)	8,850 (4.9)	67,380 (37.0)	102,004 (56.0)
Sex					
Male	95,502 (52.4)	1,934 (50.1)	4,655 (52.6)	35,612 (52.9)	53,301 (52.3)
Female	86,593 (47.6)	1,927 (49.9)	4,195 (47.4)	31,768 (47.1)	48,703 (47.7)
Race					
White	164,865 (90.5)	3,165 (82.0)	6,979 (78.9)	62,112 (92.1)	92,609 (90.8)
Black	15,342 (8.4)	614 (15.9)	1,626 (18.4)	4,688 (7.0)	8,414 (8.2)
Other ^c	1,888 (1.0)	82 (2.1)	245 (2.8)	580 (0.9)	981 (1.0)
Ethnicity					
Non-Hispanic	162,633 (89.3)	3,303 (85.5)	7,488 (84.6)	60,687 (90.1)	91,155 (89.4)
Hispanic	19,462 (10.7)	558 (14.5)	1,362 (15.4)	6,693 (9.9)	10,849 (10.6)
Neighborhood socioeconomic status^d					
Lowest	26,705 (14.7)	628 (16.3)	1,596 (18.0)	9,135 (13.6)	15,346 (15.0)
Middle-low	58,224 (32.0)	1,227 (31.8)	2,919 (33.0)	21,162 (31.4)	32,916 (32.3)
Middle-high	65,437 (35.9)	1,236 (32.0)	2,791 (31.5)	25,139 (37.3)	36,271 (35.6)
Highest	31,729 (17.4)	770 (19.9)	1,544 (17.4)	11,944 (17.7)	17,471 (17.1)
Smoking status					
Never	82,134 (45.1)	1,890 (49.0)	4,210 (47.6)	30,406 (45.1)	45,628 (44.7)
Current	21,709 (11.9)	702 (18.2)	1,825 (20.6)	6,759 (10.0)	12,423 (12.2)
Former	41,643 (22.9)	446 (11.6)	1,046 (11.8)	15,862 (23.5)	24,289 (23.8)
Unknown ^e	36,609 (20.1)	823 (21.3)	1,769 (20.0)	14,353 (21.3)	19,664 (19.3)
Anatomic site of cancer					
Ascending colon	32,860 (18.0)	333 (8.6)	1,054 (11.9)	12,001 (17.8)	19,472 (19.1)
Hepatic flexure	8,682 (4.8)	104 (2.7)	285 (3.2)	3,003 (4.5)	5,290 (5.2)
Transverse colon	15,335 (8.4)	184 (4.8)	656 (7.4)	5,072 (7.5)	9,423 (9.2)
Splenic flexure	6,291 (3.5)	90 (2.3)	358 (4.0)	1,750 (2.6)	4,093 (4.0)
Descending colon	10,938 (6.0)	208 (5.4)	616 (7.0)	3,798 (5.6)	6,316 (6.2)
Sigmoid colon	50,234 (27.6)	997 (25.8)	2,457 (27.8)	18,992 (28.2)	27,788 (27.2)
Rectosigmoid junction	20,907 (11.5)	432 (11.2)	1,130 (12.8)	7,238 (10.7)	12,107 (11.9)
Rectum	36,848 (20.2)	1,513 (39.2)	2,294 (25.9)	15,526 (23.0)	17,515 (17.2)

^a Early = localized; advanced = regional (with or without lymph node extension) or distant.

^b Column percentages except for the Total row.

^c Other race includes Asian/Pacific Islander, Native American, Asian/Indian, or Pakistani.

^d US census tract neighborhood level socioeconomic status defined as the percentage of people living below poverty level as low (20%–100%), middle-low (10% to <20%), middle-high (5% to <10%), and highest (0% to <5%).

^e Unknown smoking status refers to nonresponse or refused to respond.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

Table 2. Multivariable Logistic Regression Models Predicting Advanced Stage Colon Cancer^a Presentation at Diagnosis, Florida Cancer Data System, 1981–2013

Characteristic	All, AOR (95% CI)	Age Group	
		<50 years, AOR (95% CI)	≥ 50 years, AOR (95% CI)
Age-group (reference, ≥50 years)			
<50 years	1.53 (1.47–1.60)		NA
Sex (reference, male)			
Female	1.00 (0.98–1.02)	0.88 (0.81–0.95)	1.01 (0.99–1.03)
Race (reference, white)			
Black	1.16 (1.12–1.21)	1.15 (1.03–1.29)	1.16 (1.12–1.21)
Other ^b	1.21 (1.10–1.34)	1.43 (1.10–1.84)	1.18 (1.06–1.31)
Ethnicity (reference, non-Hispanic)			
Hispanic	1.08 (1.05–1.12)	1.09 (0.97–1.21)	1.08 (1.04–1.12)
Neighborhood socioeconomic status^c (reference, highest)			
Lowest	1.10 (1.06–1.14)	1.16 (1.01–1.33)	1.09 (1.05–1.14)
Middle-low	1.06 (1.03–1.09)	1.16 (1.04–1.30)	1.05 (1.02–1.08)
Middle-high	0.99 (0.96–1.02)	1.12 (1.00–1.25)	0.98 (0.96–1.01)
Smoking status (reference, never)			
Current	1.26 (1.22–1.30)	1.19 (1.07–1.32)	1.26 (1.22–1.31)
Former	1.05 (1.02–1.08)	1.11 (0.98–1.25)	1.05 (1.02–1.08)
Unknown	0.94 (0.91–0.96)	1.00 (0.91–1.11)	0.93 (0.91–0.96)
Anatomic site (reference, rectum)			
Ascending colon	1.49 (1.44–1.53)	2.08 (1.81–2.39)	1.45 (1.41–1.50)
Hepatic flexure	1.59 (1.52–1.67)	1.78 (1.41–2.25)	1.57 (1.49–1.65)
Transverse colon	1.70 (1.63–1.76)	2.33 (1.96–2.78)	1.66 (1.59–1.72)
Splenic flexure	2.12 (2.00–2.24)	2.61 (2.06–3.33)	2.08 (1.95–2.20)
Descending colon	1.51 (1.45–1.58)	1.97 (1.66–2.34)	1.48 (1.41–1.55)
Sigmoid colon	1.33 (1.30–1.37)	1.66 (1.50–1.83)	1.31 (1.27–1.34)
Rectosigmoid junction	1.51 (1.46–1.56)	1.75 (1.54–1.99)	1.49 (1.43–1.54)

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; NA, not applicable.

^a Regional (with or without lymph node extension) or distant.

^b Other race includes Asian/Pacific Islander, Native American, Asian/Indian, or Pakistani.

^c US census tract neighborhood level socioeconomic status defined as the percentage of people living below poverty level as low (20%–100%), middle-low (10% to <20%), middle-high (5% to <10%), and highest (0% to <5%).